A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 530 participants.
Also called NCT04157751
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 530 participants
- Registry
-
NCT04157751 -
2019-002946-19
-
- Other papers using this trial's data
- Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
- Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE
- Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE
- The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, China, Czechia, Denmark, Germany, Hungary, Italy, Japan, Netherlands, Norway, Poland, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT04157751. Randomized; double masking; primary purpose treatment. Start 2020-05-18 (actual); primary completion 2021-05-28 (actual). Results posted on 2022-06-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
- Condition
- Heart Failure
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo to Empagliflozin
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct04157751- Content hash
bc4cb3157b204d257ffa6686759560bf7b5baac8b539231f100fe4b6973b834a